CAMBRIDGE, Mass. and EXTON, Pa., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today
announced that Idera’s Chief Executive Officer, Vincent Milano will provide a corporate overview and participate in a fireside chat
discussion at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 12:45 p.m. Eastern Time at the Le
Parker Meridien Hotel in New York City.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s
website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment
of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic
oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera
has created a third generation antisense technology platform using its proprietary technology to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) rdoody@iderapharma.com
